TGFB1 and neoplasm: In contrast, the monoclonal antibody AB0023 targeting LOXL2 demonstrates superior safety and efficacy: it simultaneously suppresses tumor metastasis and TGF-β signaling activation, showing broad applicability in both oncologic and fibrotic diseases 182.